ClinicalTrials.gg
RecruitingNCT05680220Updated Mar 3, 2026

40 Hz Light Neurostimulation for Patients With Depression (FELIX)

An interventional study of Neurostimulation System (NSS): Active Setting and Neurostimulation System (NSS): Sham Setting in Major Depressive Disorder and Treatment Resistant Depression, sponsored by Klaus Martiny. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Klaus Martiny · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Depressive Disorder, Major with a site in Denmark — 10 open to participants now, 11 under way, none of them phase 3. Depressive Disorder, Major · Denmark.

Planned enrollment
27th of 36
60 · median 80
Started
2023
the only one that year
No phase
24 of 44
6 open now
Primary completion
2027-06
later than 5 of 10 live
Registered
34th of 44
by date

Among the 44 studies in Depressive Disorder, Major with a site in Denmark, this one is the 27th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2023, is one of 24 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 34th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

10 of the 44 studies in Depressive Disorder, Major with a site in Denmark are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Depressive Disorder, Major with a site in Denmark, or all of them as a file.
02

Study summary

Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory. Moreover, recent data suggest that 40 Hz light stimulation may induce neuroplasticity and reduce neuroinflammation.

In this study, the investigators aim to evaluate the antidepressant effects of 40 Hz light stimulation in Major Depressive Disorder (MDD). Patients will be exposed to 40 Hz invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) in a home setting for 1 hour each day.

Read the detailed description

Major depression is a major societal challenge worldwide and a substantial proportion of patients do not attain remission. Major depressive disorder (MDD) bears several key neurobiological similarities with Alzheimer's Disease, namely cognitive deficits, impaired neuroplasticity, neurodegeneration, and neuroinflammation. Inducing neuroplasticity and reducing neuroinflammation are thought to be key cellular targets in the treatment of MDD. However, 40 Hz light stimulation research in the context of MDD is limited.

In this double-blinded, randomized placebo-controlled trial the primary objective is to investigate the antidepressant effect of a non-invasive neurostimulation therapy using a 40 Hz masked flickering light. This study utilizes a novel way of masking light by alternating the spectral composition of white light, resulting in the flicker unnoticeable to human perception.

The primary outcome measure of this study is the estimated difference in the Hamilton Depression Rating sub-scale (HAM-D6) scores between groups at week 6. Furthermore, investigators want to assess whether 40 Hz masked flickering light therapy produces a similar early shift in neural and cognitive response to emotional information seen with antidepressant therapy and whether this predicts treatment efficacy. Suicidal ideation, sleep patterns, and quality of life will be also investigated in order to evaluate the 40 Hz masked flickering light stimulation effects on other symptoms of depression. Explorative analysis of the EEG data will be performed from baseline to week 6 for the further development and validation of EEG-based biomarkers.

A total of 60 participants will be enrolled for a six weeks treatment period followed by a two weeks follow-up period. Participants will be recruited from a psychotherapeutic outpatient unit. Medication should be unchanged for the last 4 weeks and during the study period.

03

Conditions studied

  • Major Depressive Disorder
  • Treatment Resistant Depression

Keywords

  • 40 Hz stimulation
  • Major Depressive Disorder
  • Light therapy
  • GENUS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects between 18 and 75 years of age.
  2. Subjects with a diagnosis of major depressive episode and currently experiencing a depressive episode according to
  3. Subjects with an MDI score > 21 at screening
  4. Subjects on stable medication and/or psychotherapy for at least 4 weeks before starting the trial.
  5. Subjects, who are willing to comply with the scheduled plan and are able to use the device for 1 hour per day for 6 weeks.
  6. Subjects who can understand the oral and written study information and willing to sign an .

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of photosensitive migraines and/or epileptic seizures
  2. Subjects with a known eye disorder that might be sensitive to light treatment.
  3. Subjects with a known history of bipolar disorder according to criteria
  4. Subjects with suicidal ideation corresponding to a score of 2 or more on the HAM-D 17 scale item 3 or if the patient or investigator is uncertain of the degree of suicidal risk
  5. Subjects with current psychotic symptoms. However, subjects with a prior psychotic depression or subjects with an actual psychotic depression episode that at the time of no longer fulfills the psychosis criteria are allowed to participate.
  6. Subjects with current drug or alcohol dependence based on their medical records or the M.I.N.I. interview.
  7. Subjects with a known history of borderline personality disorder
  8. Subjects currently enrolled in another treatment study.
  9. Subjects with progressive neurodegenerative or neoplastic disease.
  10. Subjects who are unable to understand the study procedures or handling of the NSS device.
  11. Subjects who are pregnant at the time of inclusion or unsafe in women of fertile age
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active Neurostimulation System (NSS)

    Exposure to the NSS device set to 40 Hz invisible spectral flicker 1 hour a day

  • Placebo comparator
    Sham Neurostimulation System (NSS)

    Exposure to the NSS device set to continuous color-matched white light for 1 hour a day

Interventions

  • DeviceNeurostimulation System (NSS): Active Setting

    Exposure to the active device for 1 hour a day for 6 weeks

  • DeviceNeurostimulation System (NSS): Sham Setting

    Exposure to the sham device for 1 hour a day for 6 weeks

06

What researchers measure

Primary outcomes

  1. Depression severity measured by Hamilton Depression Rating sub-scale (HAM-D6)

    The HAM-D6 scale is designed to rate the severity of depression by a healthcare professional. The assessment scale contains 6 items pertaining to the symptoms of depression experienced over the week. The primary endpoint is the mean difference in scores between treatments at baseline and week 6. The score range is from, 0-24 (24=highest depression level).

    Time frame: Baseline and week 6

Secondary outcomes

  1. Self-reported depression symptoms measured by Major Depression Inventory (MDI)

    The MDI is a depression self-assessment questionnaire. It consists of the 10 ICD-10 symptoms for depression. The sum of 10 questions indicates the degree of depression. The score range is from 0-50 (50=highest depression level).

    Time frame: Baseline, week 1, 3, 6 and 8.

  2. Cognition measured by Facial Expression Recognition Test (FERT)

    Assessing attention and recognition of emotional facial expressions using the FERT. The outcome is accuracy (% correct expressions identified, range: 0-100, higher is better) and response times for accurate identifications (milliseconds, range can vary quite a bit, smaller number is better because it reflect higher speed).

    Time frame: Baseline, week 1 and 6

  3. Cognition measured by Emotional Categorization and Memory test (ECMT)

    Assessing self-referent memory for emotional words using the ECMT. Outcome is response times for correct identifications during encoding phase (milliseconds, smaller better) and for recall phase: number of positive and negative words recalled (higher is better)

    Time frame: Baseline, week 1 and 6

  4. Cognition measured by Screen for Cognitive Impairment in Psychiatry (SCIP)

    Non-emotional cognition is investigated with the SCIP. Outcomes is total score as well as scores for the five subtests, in all cases higher is better (numbers correct)

    Time frame: Baseline, week 1 and 6

  5. Cognition measured by Trail Making Test B (TMT- B)

    Non-emotional cognition investigated with the Trail Making Test B (TMT- B). Outcome is time in seconds to complete the task, lower is better (higher speed)

    Time frame: Baseline, week 1 and 6

  6. Sleep quality measured by Pittsburgh Sleep Quality Index (PSQI)

    PSQI consist of seven component scores that are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality. A cut-off of 5 is recognized a indicative of sleep problems.

    Time frame: Baseline, week 3, 6 and 8

  7. Sleep duration

    Average sleep duration assessed over last 7 days will be logged by the participants using a sleep diary.

    Time frame: Baseline, week 3, 6 and 8

  8. Sleep timing

    Average sleep timing will be assessed over last 7 days logged by the participants using a sleep diary.

    Time frame: Baseline, week 3, 6 and 8

  9. Quality of Life measured by WHO quality of life index (WHO-5)

    The WHO-5 score ranges from 0 to 25, with 0 representing worst possible and 25 representing best possible quality of life. To obtain a percentage score ranging from 0 to 100, the raw score is multiplied by 4. A percentage score of 0 represents worst possible, whereas a score of 100 represents best possible quality of life. A 10% difference indicates a significant change.

    Time frame: Baseline, week 3,6 and 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Adaikkan C, Middleton SJ, Marco A, Pao PC, Mathys H, Kim DN, Gao F, Young JZ, Suk HJ, Boyden ES, McHugh TJ, Tsai LH. Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection. Neuron. 2019 Jun 5;102(5):929-943.e8. doi: 10.1016/j.neuron.2019.04.011. Epub 2019 May 7. PubMed 31076275 ↗
  • Chen X, Shi X, Wu Y, Zhou Z, Chen S, Han Y, Shan C. Gamma oscillations and application of 40-Hz audiovisual stimulation to improve brain function. Brain Behav. 2022 Dec;12(12):e2811. doi: 10.1002/brb3.2811. Epub 2022 Nov 14. PubMed 36374520 ↗
  • Cimenser A, Hempel E, Travers T, Strozewski N, Martin K, Malchano Z, Hajos M. Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer's Disease Patients. Front Syst Neurosci. 2021 Sep 24;15:746859. doi: 10.3389/fnsys.2021.746859. eCollection 2021. PubMed 34630050 ↗
  • Colgin LL, Moser EI. Gamma oscillations in the hippocampus. Physiology (Bethesda). 2010 Oct;25(5):319-29. doi: 10.1152/physiol.00021.2010. PubMed 20940437 ↗
  • Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016 Mar;22(3):238-49. doi: 10.1038/nm.4050. PubMed 26937618 ↗
  • Fitzgerald PJ, Watson BO. Gamma oscillations as a biomarker for major depression: an emerging topic. Transl Psychiatry. 2018 Sep 4;8(1):177. doi: 10.1038/s41398-018-0239-y. PubMed 30181587 ↗
  • Godlewska BR, Harmer CJ. Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment. Psychopharmacology (Berl). 2021 May;238(5):1265-1278. doi: 10.1007/s00213-019-05448-0. Epub 2020 Jan 15. PubMed 31938879 ↗
  • Martiny K, Lunde M, Unden M, Dam H, Bech P. Adjunctive bright light in non-seasonal major depression: results from clinician-rated depression scales. Acta Psychiatr Scand. 2005 Aug;112(2):117-25. doi: 10.1111/j.1600-0447.2005.00574.x. PubMed 15992393 ↗
  • Agger MP, Carstensen MS, Henney MA, Hansen LS, Baandrup AO, Nguyen M, Petersen PM, Madsen KH, Kjaer TW. Novel Invisible Spectral Flicker Induces 40 Hz Neural Entrainment with Similar Spatial Distribution as 40 Hz Stroboscopic Light. J Alzheimers Dis. 2022;88(1):335-344. doi: 10.3233/JAD-220081. PubMed 35570490 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jun 2027, 44 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 44 months is above that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2023
First posted
Jan 11, 2023
StartActual
Oct 5, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05680220
Lead sponsor
Klaus Martiny
Collaborators
Technical University of Denmark, OptoCeutics
Responsible party
Klaus Martiny (Professor, Head of NID-Group, University Hospital Bispebjerg and Frederiksberg) — Sponsor-investigator
First posted
Jan 11, 2023
Start date
Oct 5, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Mar 3, 2026

Study contacts

Klaus Martiny
Contact
klaus.martiny@regionh.dk
+45 38 64 71 00
Malina Ploug Larsen
Contact
malina.ploug.larsen@regionh.dk
Klaus Martiny
principal investigator · Senior Consultant at Psychiatric Centre Copenhagen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion